Imatinib resistance: Obstacles and opportunities

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Objective.-To review the current status of resistance to imatinib mesylate (IM) in patients with chronic myelogenous leukemia, and the obstacles and opportunities presented by the development of this resistance. Data Sources and Study Selection.-Review of selected studies obtained from a MEDLINE search encompassing the years 1950 to 2004. Data Extraction and Data Synthesis.-Relevant information from the selected studies was abstracted and summarized. Conclusions.-The identification of the Philadelphia chromosome and the subsequent discovery that it represents a translocation between the long arms of chromosomes 9 and 22 producing an aberrant tyrosine kinase, known as BCR-ABL1, has catalyzed our understanding and treatment of this hematologic malignancy. An extensive search for molecules to block the aberrant BCR-ABL1 protein resulted in the development of IM as an orally bio-available agent with remarkable efficacy in producing hematologic, cytogenetic, and molecular remissions. However, follow-up of patients treated with IM has demonstrated that some patients can develop resistance to IM with progression of their leukemia. Multiple mechanisms of resistance have been identified. The dominant mechanism appears to be mutations in the kinase domain of BCR-ABL1, which result in altered affinity of IM for the BCR-ABL1 protein. Recently, small-molecule, combined SRC and ABL1 inhibitors have been developed and entered into clinical trials. These inhibitors appear effective in inhibiting most of the mutant BCR-ABL1 molecules that are resistant to IM. The rapid development of new therapies for treatment of chronic myelogenous leukemia brings the promise that this disorder can be cured or controlled in many patients with oral drugs that have a low toxicity profile.

Original languageEnglish (US)
Pages (from-to)669-679
Number of pages11
JournalArchives of Pathology and Laboratory Medicine
Volume130
Issue number5
StatePublished - May 2006

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chromosomes, Human, Pair 22
Philadelphia Chromosome
Chromosomes, Human, Pair 9
Information Storage and Retrieval
Hematologic Neoplasms
MEDLINE
Cytogenetics
Protein-Tyrosine Kinases
Imatinib Mesylate
Leukemia
Proteins
Phosphotransferases
Therapeutics
Clinical Trials
Mutation
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Cite this

Imatinib resistance : Obstacles and opportunities. / Litzow, Mark R.

In: Archives of Pathology and Laboratory Medicine, Vol. 130, No. 5, 05.2006, p. 669-679.

Research output: Contribution to journalArticle

@article{c93e510e0f94436db6b6cae1b7b707fe,
title = "Imatinib resistance: Obstacles and opportunities",
abstract = "Objective.-To review the current status of resistance to imatinib mesylate (IM) in patients with chronic myelogenous leukemia, and the obstacles and opportunities presented by the development of this resistance. Data Sources and Study Selection.-Review of selected studies obtained from a MEDLINE search encompassing the years 1950 to 2004. Data Extraction and Data Synthesis.-Relevant information from the selected studies was abstracted and summarized. Conclusions.-The identification of the Philadelphia chromosome and the subsequent discovery that it represents a translocation between the long arms of chromosomes 9 and 22 producing an aberrant tyrosine kinase, known as BCR-ABL1, has catalyzed our understanding and treatment of this hematologic malignancy. An extensive search for molecules to block the aberrant BCR-ABL1 protein resulted in the development of IM as an orally bio-available agent with remarkable efficacy in producing hematologic, cytogenetic, and molecular remissions. However, follow-up of patients treated with IM has demonstrated that some patients can develop resistance to IM with progression of their leukemia. Multiple mechanisms of resistance have been identified. The dominant mechanism appears to be mutations in the kinase domain of BCR-ABL1, which result in altered affinity of IM for the BCR-ABL1 protein. Recently, small-molecule, combined SRC and ABL1 inhibitors have been developed and entered into clinical trials. These inhibitors appear effective in inhibiting most of the mutant BCR-ABL1 molecules that are resistant to IM. The rapid development of new therapies for treatment of chronic myelogenous leukemia brings the promise that this disorder can be cured or controlled in many patients with oral drugs that have a low toxicity profile.",
author = "Litzow, {Mark R}",
year = "2006",
month = "5",
language = "English (US)",
volume = "130",
pages = "669--679",
journal = "Archives of Pathology and Laboratory Medicine",
issn = "0003-9985",
publisher = "College of American Pathologists",
number = "5",

}

TY - JOUR

T1 - Imatinib resistance

T2 - Obstacles and opportunities

AU - Litzow, Mark R

PY - 2006/5

Y1 - 2006/5

N2 - Objective.-To review the current status of resistance to imatinib mesylate (IM) in patients with chronic myelogenous leukemia, and the obstacles and opportunities presented by the development of this resistance. Data Sources and Study Selection.-Review of selected studies obtained from a MEDLINE search encompassing the years 1950 to 2004. Data Extraction and Data Synthesis.-Relevant information from the selected studies was abstracted and summarized. Conclusions.-The identification of the Philadelphia chromosome and the subsequent discovery that it represents a translocation between the long arms of chromosomes 9 and 22 producing an aberrant tyrosine kinase, known as BCR-ABL1, has catalyzed our understanding and treatment of this hematologic malignancy. An extensive search for molecules to block the aberrant BCR-ABL1 protein resulted in the development of IM as an orally bio-available agent with remarkable efficacy in producing hematologic, cytogenetic, and molecular remissions. However, follow-up of patients treated with IM has demonstrated that some patients can develop resistance to IM with progression of their leukemia. Multiple mechanisms of resistance have been identified. The dominant mechanism appears to be mutations in the kinase domain of BCR-ABL1, which result in altered affinity of IM for the BCR-ABL1 protein. Recently, small-molecule, combined SRC and ABL1 inhibitors have been developed and entered into clinical trials. These inhibitors appear effective in inhibiting most of the mutant BCR-ABL1 molecules that are resistant to IM. The rapid development of new therapies for treatment of chronic myelogenous leukemia brings the promise that this disorder can be cured or controlled in many patients with oral drugs that have a low toxicity profile.

AB - Objective.-To review the current status of resistance to imatinib mesylate (IM) in patients with chronic myelogenous leukemia, and the obstacles and opportunities presented by the development of this resistance. Data Sources and Study Selection.-Review of selected studies obtained from a MEDLINE search encompassing the years 1950 to 2004. Data Extraction and Data Synthesis.-Relevant information from the selected studies was abstracted and summarized. Conclusions.-The identification of the Philadelphia chromosome and the subsequent discovery that it represents a translocation between the long arms of chromosomes 9 and 22 producing an aberrant tyrosine kinase, known as BCR-ABL1, has catalyzed our understanding and treatment of this hematologic malignancy. An extensive search for molecules to block the aberrant BCR-ABL1 protein resulted in the development of IM as an orally bio-available agent with remarkable efficacy in producing hematologic, cytogenetic, and molecular remissions. However, follow-up of patients treated with IM has demonstrated that some patients can develop resistance to IM with progression of their leukemia. Multiple mechanisms of resistance have been identified. The dominant mechanism appears to be mutations in the kinase domain of BCR-ABL1, which result in altered affinity of IM for the BCR-ABL1 protein. Recently, small-molecule, combined SRC and ABL1 inhibitors have been developed and entered into clinical trials. These inhibitors appear effective in inhibiting most of the mutant BCR-ABL1 molecules that are resistant to IM. The rapid development of new therapies for treatment of chronic myelogenous leukemia brings the promise that this disorder can be cured or controlled in many patients with oral drugs that have a low toxicity profile.

UR - http://www.scopus.com/inward/record.url?scp=33646675638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646675638&partnerID=8YFLogxK

M3 - Article

C2 - 16683885

AN - SCOPUS:33646675638

VL - 130

SP - 669

EP - 679

JO - Archives of Pathology and Laboratory Medicine

JF - Archives of Pathology and Laboratory Medicine

SN - 0003-9985

IS - 5

ER -